SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Yizhou Quan 1 , Naitao Wang 1 , Qianqian Chen 1 , Jin Xu 1 , Wei Cheng 2 , Meijuan Di 3 , Weiliang Xia 1 and Wei-Qiang Gao 1,4 1 State Key Laboratory of Oncogenes and Related Genes, Renji-MedX Clinical Stem Cell Research Center, Ren Ji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China 2 Department of Urology, First People’s Hospital of Xiaoshan, Hangzhou, Zhejiang, China 3 Department of Pathology, First People’s Hospital of Xiaoshan, Hangzhou, Zhejiang, China 4 Collaborative Innovation Center of Systems Biomedicine, Shanghai, China Correspondence to: Weiliang Xia, email: // Wei-Qiang Gao, email: // Keywords : SIRT3, prostate cancer, oncoprotein, PI3K-Akt pathway, c-MYC Received : March 23, 2015 Accepted : June 25, 2015 Published : July 03, 2015 Abstract SIRT3 is involved in aging-related diseases including cancer, but its role in prostate cancer and detailed regulatory function are not known. We found that SIRT3 was moderately down-regulated in prostate carcinomas. Overexpression of SIRT3 by lentiviral transfection inhibited prostate cancer growth both in vitro and in vivo , whereas knockdown of SIRT3 increased prostate tumor growth. Mechanistically, the tumor suppression effect of SIRT3 was achieved via its inhibition of the PI3K/Akt pathway. Notably, upregulation of SIRT3 suppressed the phosphorylation of Akt, leading to the ubiquitination and degradation of oncoprotein c-MYC; this could be attenuated by constitutive activation of PI3K/Akt signaling. Collectively, our results unveiled SIRT3’s tumor suppressive function and the underlying mechanism in prostate cancer, which might provide therapeutic implications for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742 · cited 1×
“Thus far antioxidant therapies for cancer patients have not been successful because antioxidants could hardly access to the mitochondria-localized pools of ROS [10, 11].”
BackgroundCalorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation
Qiu, X., Brown, K., Hirschey, M. D., Verdin, E., & Chen, D. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.015 · Cited by 1,310 · cited 1×
“SIRT3 has been regarded as an aging-related protein and most studies of SIRT3 have focused on longevity [37-39].”
BackgroundBerthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Kim, H.-S., Patel, K., Muldoon-Jacobs, K., Bisht, K. S., Aykin-Burns, N., Pennington, J. D., van der Meer, R., Nguyen, P., Savage, J., Owens, K. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.023 · Cited by 785 · cited 3×
“SIRT3 was first reported as a tumor suppressor in breast carcinoma [12].”
BackgroundSIRT3 Opposes Reprogramming of Cancer Cell Metabolism through HIF1α Destabilization
Finley, L. W. S., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., Teruya-Feldstein, J., Moreira, P. I., Cardoso, S. M., Clish, C. B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.014 · Cited by 782
Shi, T., Wang, F., Stieren, E., & Tong, Q. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414670200 · Cited by 712 · cited 1×
“SIRT3 has been regarded as an aging-related protein and most studies of SIRT3 have focused on longevity [37-39].”
BackgroundSIRT3 Reverses Aging-Associated Degeneration
Brown, K., Xie, S., Qiu, X., Mohrin, M., Shin, J., Liu, Y., Zhang, D., Scadden, D. T., & Chen, D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.005 · Cited by 436 · cited 2×
“SIRT3 is a mitochrondria-located antioxidants trigger [9, 12] and ROS can activate the PI3K/Akt pathway [26, 36].”
BackgroundTargeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186 · cited 1×
“Targeting c-MYC could put a brake on the rapid growth of cancer [35, 41, 42], but c-MYC is currently undruggable.”
Background
Cited by
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
Sirtuins in glucose and lipid metabolism
Ye, X., Li, M., Hou, T., Gao, T., Zhu, W.-G., & Yang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.12157 · Cited by 215
“Moreover, SIRT3 inhibits cancer cell proliferation in prostate cancer and gastric cancer [80, 81].”
BackgroundThe role of mitochondrial sirtuins in health and disease
Osborne, B., Bentley, N. L., Montgomery, M. K., & Turner, N. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.197 · Cited by 179
Myricetin: Targeting signaling networks in cancer and its implication in chemotherapy
Javed, Z., Khan, K., Herrera-Bravo, J., Naeem, S., Iqbal, M. J., Raza, Q., Sadia, H., Raza, S., Bhinder, M., Calina, D., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02663-2 · Cited by 93
“SIRT3 also suppresses Akt via the LKB1/AMPK pathway [79, 112].”
Background
Metadata
- Authors
- Quan, Y., Wang, N., Chen, Q., Xu, J., Cheng, W., Di, M., Xia, W., & Gao, W.-Q.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-07-03
- Volume
- 6
- Issue
- 28
- Pages
- 26494-26507
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1606861223
- Cited by
- 76
- References
- 9
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.